CTOR
Citius Oncology Inc.

1,358
Mkt Cap
$101.05M
Volume
84,070.00
52W High
$6.19
52W Low
$0.5506
PE Ratio
-6.36
CTOR Fundamentals
Price
$1.17
Prev Close
$1.21
Open
$1.23
50D MA
$1.70
Beta
-2.29
Avg. Volume
263,343.39
EPS (Annual)
-$0.3108
P/B
2.67
Loading...
Loading...
News
all
press releases
Citius Oncology (NASDAQ:CTOR) Trading Down 6% - Here's What Happened
Citius Oncology (NASDAQ:CTOR) Stock Price Down 6% - Should You Sell...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR...
PR Newswire·1mo ago
News Placeholder
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to...
PR Newswire·1mo ago
News Placeholder
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business...
PR Newswire·9mo ago
News Placeholder
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services Citius Pharmaceuticals and Citius Oncology Announce Unique...
PR Newswire·10mo ago
News Placeholder
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch...
PR Newswire·11mo ago
News Placeholder
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives...
PR Newswire·11mo ago
News Placeholder
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update...
PR Newswire·11mo ago
News Placeholder
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides...
PR Newswire·11mo ago
News Placeholder
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer...
PR Newswire·1y ago

Latest CTOR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.